Showcasing AI-Powered Lung Cancer Screening Innovations Backed by Pivotal Clinical Studies

BioAffinity Technologies Secures New Canadian Patent for CyPath® Lung, Its Noninvasive Lung Cancer Test

A biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by…

Read MoreBioAffinity Technologies Secures New Canadian Patent for CyPath® Lung, Its Noninvasive Lung Cancer Test

HarmonyCares Chooses athenahealth to Support Physician-Led Integrated Care and Drive Practice Growth

A leading provider of network-enabled software and services for healthcare practices nationwide, today announced that HarmonyCares, a national value-based provider of in-home primary care services for individuals with complex healthcare needs, has implemented athenaOne® to enhance provider and patient experiences and improve…

Read MoreHarmonyCares Chooses athenahealth to Support Physician-Led Integrated Care and Drive Practice Growth
EdgeOne Medical Appoints Michael Denzer as VP of Client Relations to Boost Innovation and Partnerships

EdgeOne Medical Appoints Michael Denzer as VP of Client Relations to Boost Innovation and Partnerships

EdgeOne Medical, a professional service organization focused on device development service for combination products in the bio-pharmaceutical industry is pleased to announce the appointment of Mr. Michael Denzer as Vice President of Client Relations. This role reflects what matters most…

Read MoreEdgeOne Medical Appoints Michael Denzer as VP of Client Relations to Boost Innovation and Partnerships
Innovaccer Unveils AI Solution to Cut Readmissions and Improve Care Outcomes

Innovaccer Unveils AI Solution to Cut Readmissions and Improve Care Outcomes

Innovaccer Inc., a leading healthcare AI company, today announced the launch of a comprehensive, AI-powered Readmissions Management Solution designed to help health systems and providers reduce avoidable readmissions, standardize transitional care management (TCM) protocols, reduce exposure to penalties, and optimize hospital capacity…

Read MoreInnovaccer Unveils AI Solution to Cut Readmissions and Improve Care Outcomes
DeciBio Consulting Appoints Carl Schoellhammer as Partner to Bolster Leadership in Advanced Therapies and Strategy

DeciBio Consulting Names Carl Schoellhammer Partner to Drive Advanced Therapies Strategy

DeciBio Consulting, LLC, a precision medicine-focused strategic consulting and market intelligence firm, has promoted Carl Schoellhammer, Ph.D., to Partner. Carl leads the firm’s advanced therapies practice and serves as Managing Director of the DeciBio BroadOak BioTools Venture Fund, a joint…

Read MoreDeciBio Consulting Names Carl Schoellhammer Partner to Drive Advanced Therapies Strategy
CareDx Announces Draft LCD Supporting Coverage for Transplant Rejection Surveillance Testing

CareDx Announces Draft LCD Supporting Coverage for Transplant Rejection Surveillance Testing

CareDx Announces Draft LCD Supporting Coverage for Transplant Rejection Surveillance Testing The Transplant Company – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced…

Read MoreCareDx Announces Draft LCD Supporting Coverage for Transplant Rejection Surveillance Testing
Biocytogen and BeiGene Sign Licensing Deal to Advance Antibody-Based Drug Development

Biocytogen and BeiGene Sign Licensing Deal to Advance Antibody-Based Drug Development

Biocytogen Holdings, a global biotechnology company driving drug discovery with innovative technologies, today announced it has entered into a global licensing agreement for antibody molecules with BeiGene, a global innovator in oncology treatment. BeiGene has previously obtained the authorization to…

Read MoreBiocytogen and BeiGene Sign Licensing Deal to Advance Antibody-Based Drug Development